©2019 by Galea Therapeutics Inc.     -     info@galeatherapeutics.com      -     Privacy Policy

Fatty Liver Disease (FLD) is a rising epidemic originated in obesity and heavy drinking, affecting up to 26% of adult population.

 

It's a chronic condition that can progress into liver inflammation, fibrosis, liver failure and liver cancer.

 

We are developing therapies to stop this.

FLD is a chronic condition in which excess fat builds up in the liver.

It is originated either in metabolic syndrome (obesity, diabetes, hyperlipidemia) or in excessive alcohol consumption.

Having both phenomena a strong and rising prevalence in the global population, liver chronic disease has become a high socio-economic burden epidemic.

Some cases will progress up to the point of cirrhosis or liver cancer, which every year are responsible for the death of 720,000 and 470,00 people respectively.

Fatty Liver Disease

 
 

R&D Approach

Additionally, moderation of ingestive and drinking habits should be considered as an integral part of the therapy.

Therefore, the ideal FLD drug should target the various physiological mechanisms of the disease as early as possible to avoid fibrosis onset, as well as help patients adjust their ingestive and drinking habits.

FLD presents multiple physiological mechanisms that should be targeted simultaneously in order to maximice therapeutic efficacy.

We are developing a uniquely comprehensive therapy that addresses the multifactorial pathogenesis of both NAFLD & ALD, while also helps patients with their eating and drinking habits.

Programs

A novel class of small molecules with clear advantages over existing approaches.

GAL-072 has demonstrated robust in vivo proof of concept in animal models of liver steatosis, significantly reducing liver fat content, increasing fat degradation and reducing inflammation, while also reducing food and alcohol voluntary intake. IND-enabling toxicology and safety pharmacology are planned for 2020.

Our lead compound should provide a broad therapeutic solution from early stages of the disease,

thereby having a profound impact on the management of FLD.

 

Partnerships